A third Long Island company has jumped into the global race to produce COVID-19 vaccines. Hauppauge-based Covaxx, a spinout of United Biomedical Inc., has begun testing its lead vaccine candidate, UB-612, in a Phase 1 human trial in Taiwan. Further trials are planned for Nebraska and Brazil pending regulatory approval.

Pfizer is hustling to scale up production of its vaccine candidate ahead of a possible approval in November, the drugmaker’s U.K. chief said Sunday. Meanwhile, AstraZeneca and the University of Oxford’s shot could snare authorization in the U.K. for high-risk patients by year-end, England’s deputy chief medical officer said. UNICEF is stockpiling single-dose syringes, disposal boxes […]

James Archetto, Vice President at Gaumard Scientific, designers and manufacturers of state-of-the-art, robot-like, patient simulators, discusses the advantages of simulation-based training and how it is improving COVID-19 readiness along with helping clinicians to develop the skills to use a ventilator.  The simulators are incredibly life-like and engage the emotions of the learner.